Peak Bio, Inc. Common Stock
PKBO
PKBO was delisted on the 9th of January, 2023.
30 hedge funds and large institutions have $33.4M invested in Peak Bio, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 2 closing their positions.
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
300% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 2
52% more capital invested
Capital invested by funds: $21.9M → $33.4M (+$11.5M)
25% more funds holding
Funds holding: 24 → 30 (+6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$7.03M |
| 2 |
WRBC
W.R. Berkley Corp
Greenwich,
Connecticut
|
+$1.11M |
| 3 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$663K |
| 4 |
DKCM
Davidson Kempner Capital Management
New York
|
+$475K |
| 5 |
PMAM
Picton Mahoney Asset Management
Toronto,
Ontario, Canada
|
+$388K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$1.23M |
| 2 |
KIM
Karpus Investment Management
Pittsford,
New York
|
-$95.1K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$36.1K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$18K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CM
26
Crestline Management
Fort Worth,
Texas
| $205K | – | – | – |
|
|
RCM
27
Rivernorth Capital Management
West Palm Beach,
Florida
| $196K | +$194K | +20,000 | New |
|
|
RA
28
RiverPark Advisors
New York
| $133K | – | – | – |
|
29
UBS Group
Zurich,
Switzerland
| $15K | +$14.6K | +1,500 | New |
|
|
TRCT
30
Tower Research Capital (TRC)
New York
| $1K | – | – | – |
|
|
MP
31
Mangrove Partners
Greenwich,
Connecticut
| – | -$1.23M | -126,844 | Closed |
|
|
PAM
32
Panagora Asset Management
Boston,
Massachusetts
| – | -$18K | -1,810 | Closed |
|
PKBO Hedge Fund Activity: Q3 2021 in Review
30 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Peak Bio, Inc. Common Stock (PKBO) for Q3 2021, worth a combined $33.4M — up 52% from $21.9M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new PKBO positions and 2 closed out — a net gain of 6 holders — while 8 added to existing stakes and 2 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $7.03M. The largest seller was Mangrove Partners, exiting entirely with an estimated $1.23M sold.
- 30 institutional investors held Peak Bio, Inc. Common Stock (PKBO) as of Q3 2021, up from 24 in Q2 2021.
- Funds reported $33.4M of Peak Bio, Inc. Common Stock stock for Q3 2021, up 52% quarter-over-quarter.
- 8 funds opened new Peak Bio, Inc. Common Stock positions in Q3 2021 and 2 closed out, a net change of +6 holders.
- The largest Peak Bio, Inc. Common Stock buyer in Q3 2021 was Deerfield Management, an estimated $7.03M added.
- The largest Peak Bio, Inc. Common Stock seller in Q3 2021 was Mangrove Partners, an estimated $1.23M sold.
Based on aggregated 13F filings for Q3 2021.